View printer-friendly version << Back

Novavax to Participate in Phacilitate Vaccine Forum

ROCKVILLE, Md., Jan. 17 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today announced the company's participation in the Phacilitate Vaccine Forum, a three-day conference that begins Monday at the Marriott Waterfront Hotel in Baltimore, MD.

The conference focuses on an array of global business, regulatory, investment and public policy issues across a broad range of diseases that are the targets of both prophylactic and therapeutic vaccines. Speakers include vaccine developers, government agencies, non-governmental organizations and analysts.

Dr. Rick Bright, Novavax's Vice President of Global Influenza Programs, will discuss "Virus-Like Particle (VLP) Vaccines for Seasonal and Pandemic Flu" at 4:25 p.m. on Monday, January 22.

Novavax President and Chief Executive Officer Dr. Rahul Singhvi will deliver a presentation entitled "A Holistic Vaccine Solution to the Pandemic Influenza Threat" at 3:40 p.m. on Tuesday, January 23. Immediately following the presentation, Dr. Singhvi will participate in a panel discussion on the partnership and business development strategies in the vaccine value chain.


Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.

SOURCE Novavax, Inc.

CONTACT: Mariann Caprino, Novavax, +1-240-268-2029

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.